MX2014013341A - Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. - Google Patents

Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Info

Publication number
MX2014013341A
MX2014013341A MX2014013341A MX2014013341A MX2014013341A MX 2014013341 A MX2014013341 A MX 2014013341A MX 2014013341 A MX2014013341 A MX 2014013341A MX 2014013341 A MX2014013341 A MX 2014013341A MX 2014013341 A MX2014013341 A MX 2014013341A
Authority
MX
Mexico
Prior art keywords
substituted
patient
retina
compound
unsubstituted
Prior art date
Application number
MX2014013341A
Other languages
English (en)
Spanish (es)
Inventor
Olof Bavik Claes
Hayes Henry Susan
Kubota Ryo
A Kuksa Vladimir
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of MX2014013341A publication Critical patent/MX2014013341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MX2014013341A 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. MX2014013341A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643178P 2012-05-04 2012-05-04
US201261643058P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201361781907P 2013-03-14 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Publications (1)

Publication Number Publication Date
MX2014013341A true MX2014013341A (es) 2015-06-02

Family

ID=49515046

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013341A MX2014013341A (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
MX2020001835A MX386024B (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001835A MX386024B (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Country Status (18)

Country Link
US (4) US9957224B2 (enExample)
EP (2) EP2844636B1 (enExample)
JP (6) JP2015518491A (enExample)
KR (1) KR20150013240A (enExample)
CN (3) CN104411678A (enExample)
AU (1) AU2013256029A1 (enExample)
BR (1) BR112014027571B1 (enExample)
CA (1) CA2872433C (enExample)
EA (1) EA201492031A1 (enExample)
ES (1) ES2792923T3 (enExample)
HK (2) HK1203478A1 (enExample)
IL (1) IL235446A0 (enExample)
MX (2) MX2014013341A (enExample)
PH (1) PH12014502449A1 (enExample)
SG (1) SG11201407162SA (enExample)
TW (1) TW201406707A (enExample)
WO (1) WO2013166449A2 (enExample)
ZA (1) ZA201408592B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922548A (en) 2007-10-05 2009-06-01 Acucela Inc Alkoxy compounds for disease treatment
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
AU2012294342B2 (en) 2011-08-10 2017-07-27 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
HK1210969A1 (en) 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP2016512528A (ja) * 2013-03-12 2016-04-28 アクセラ インコーポレイテッド 眼疾患及び眼障害を治療するための置換された３−フェニルプロピルアミン誘導体
EP3195838B1 (en) 2013-03-14 2018-08-22 Optimedica Corporation Laser capsulovitreotomy
US11447568B2 (en) 2014-04-10 2022-09-20 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
EP3585366A4 (en) 2017-02-27 2021-08-04 Case Western Reserve University VISUAL CYCLE MODULATORS
EP3733050B1 (en) * 2017-12-28 2025-02-26 Nikon Corporation Image processing method, image processing program, image processing device, image display device, and image display method
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
JP2021529068A (ja) 2018-07-07 2021-10-28 アキュセラ インコーポレイテッド 網膜低酸素症を防止するためのデバイス
US11402662B2 (en) 2018-07-30 2022-08-02 Acucela Inc. Optical designs of electronic contact lens to decrease myopia progression
WO2020078865A1 (en) * 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
CN112804999B (zh) * 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
JPWO2020240867A1 (enExample) * 2019-05-31 2020-12-03
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
JP2022542965A (ja) 2019-07-31 2022-10-07 アキュセラ インコーポレイテッド 画像を網膜上に投影するためのデバイス
US11733545B2 (en) 2019-09-16 2023-08-22 Acucela Inc. Assembly process for an electronic soft contact lens designed to inhibit progression of myopia
TW202203521A (zh) 2020-02-21 2022-01-16 美商艾尤席拉有限公司 電子隱形眼鏡之充電盒
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
EP4150398A4 (en) 2020-05-13 2024-10-09 Acucela Inc. ELECTRO-SWITCHABLE GLASSES FOR MYOPIA TREATMENT
KR20230020951A (ko) 2020-06-08 2023-02-13 어큐셀라 인코포레이티드 굴절 이상을 치료하기 위한 주변 망막에 대한 디포커스된 이미지의 투영
EP4162316A4 (en) 2020-06-08 2024-10-23 Acucela Inc. Stick on devices using peripheral defocus to treat progressive refractive error
AU2021288457A1 (en) 2020-06-08 2023-01-05 Acucela Inc. Lens with asymmetric projection to treat astigmatism
US11281022B2 (en) * 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
WO2022245697A1 (en) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
US20240274295A1 (en) * 2021-06-03 2024-08-15 Osaka University Method for screening for retinopathy of prematurity, apparatus for screening for retinopathy of prematurity, and learned model
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024258981A2 (en) * 2023-06-12 2024-12-19 Synaptogenix, Inc. Methods for repairing nerve damage using pkc activating therapeutic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
HRP20040406A2 (en) * 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US9421175B2 (en) * 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008131368A2 (en) * 2007-04-20 2008-10-30 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
CN103664637B (zh) * 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
TW200922548A (en) 2007-10-05 2009-06-01 Acucela Inc Alkoxy compounds for disease treatment
CL2008003120A1 (es) 2007-11-01 2009-10-09 Acucela Inc Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
GB2463151A (en) 2008-09-05 2010-03-10 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
WO2010048332A2 (en) 2008-10-22 2010-04-29 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
JP2021075576A (ja) 2021-05-20
CA2872433A1 (en) 2013-11-07
EP2844636A4 (en) 2016-03-09
JP2023059991A (ja) 2023-04-27
BR112014027571A2 (pt) 2017-07-18
KR20150013240A (ko) 2015-02-04
WO2013166449A3 (en) 2014-01-30
US20180346407A1 (en) 2018-12-06
AU2013256029A1 (en) 2014-12-04
US11795136B2 (en) 2023-10-24
JP2025069362A (ja) 2025-04-30
SG11201407162SA (en) 2014-11-27
PH12014502449A1 (en) 2015-01-12
US10730825B2 (en) 2020-08-04
MX2020001835A (es) 2021-09-09
TW201406707A (zh) 2014-02-16
BR112014027571B1 (pt) 2021-08-31
US9957224B2 (en) 2018-05-01
US20240308951A1 (en) 2024-09-19
EP2844636B1 (en) 2020-04-22
CA2872433C (en) 2022-06-28
ZA201408592B (en) 2017-09-27
ES2792923T3 (es) 2020-11-12
JP2018024702A (ja) 2018-02-15
CN116850163A (zh) 2023-10-10
CN104411678A (zh) 2015-03-11
US20210171435A1 (en) 2021-06-10
HK1203478A1 (en) 2015-10-30
EP3741742A1 (en) 2020-11-25
IL235446A0 (en) 2014-12-31
JP2020023535A (ja) 2020-02-13
HK1246646A1 (zh) 2018-09-14
MX386024B (es) 2025-03-18
WO2013166449A2 (en) 2013-11-07
US20140039048A1 (en) 2014-02-06
EP2844636A2 (en) 2015-03-11
EA201492031A1 (ru) 2015-05-29
JP2015518491A (ja) 2015-07-02
CN107865830A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
US20240308951A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
Martinez-Aguila et al. Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions
JP2023509336A (ja) 過剰血管新生に関連する眼疾患を治療する化合物
Calvo et al. Topical timolol for infantile hemangioma of the eyelid.
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
JP6908616B2 (ja) 網膜疾患の治療のためのミラベグロン
CN117177755A (zh) 一种调节神经病变的方法
JPH06206820A (ja) Ｍ１−選択的な抗ムスカリン性ピリドベンゾジアゼピノン類を含む眼科用薬剤
HK40038867A (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
Zhang et al. Iridal posterior pigment epithelial detachment induced by pilocarpine: a case report
WO2024163858A1 (en) Haloperidol derivatives, pharmaceutical composition comprising said derivatives, and therapeutic uses thereof
Nigam et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
Sgambellone Histamine H3 receptor (H3R) antagonist-Nitric Oxide (NO) donor hybrid compounds as a new therapeutic strategy for the treatment of glaucoma and retinal neuroprotection
CA3028924C (en) Salbutamol-containing ophthalmic medicament
EA051012B1 (ru) Соединения, являющиеся антагонистами trpa1 каналов, для применения при дегенеративных заболеваниях сетчатки
Williamson et al. 14 Medical Therapy for Glaucoma
RU2480252C1 (ru) Способ лечения больных с непролиферативной диабетической ретинопатией
Alio et al. Diagnosis and treatment of amblyopia
Jordan Time-of-day Influences on Emmetropization: Effects of Visual Stimuli, a Dopamine Agonist and Choroidal Growth Factors
Jim Cortical activity following restoration of elevated intraocular pressures to normal pre-laser pressures in a primate model of glaucoma
Kuriakose Management of Macular Edema Secondary to Branch Retinal Vein Occlusion with Intravitreal Bevacizumab and Macular Grid Laser

Legal Events

Date Code Title Description
FG Grant or registration